Company Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer.
The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.
The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer.
Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Apr 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Daniel Hicklin |
Contact Details
Address: 200 Talcott Ave, 2nd Floor Watertown, Massachusetts 02472 United States | |
| Phone | 617 952 0555 |
| Website | werewolftx.com |
Stock Details
| Ticker Symbol | HOWL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001785530 |
| CUSIP Number | 95075A107 |
| ISIN Number | US95075A1079 |
| Employer ID | 82-3523180 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Daniel J. Hicklin Ph.D. | Founder, Chief Executive Officer, President, Secretary and Director |
| Timothy W. Trost CPA | Chief Financial Officer, Treasurer and Assistant Secretary |
| Dr. Randi Isaacs M.D. | Chief Medical Officer |
| Dr. William Winston Ph.D. | Senior Vice President of Research |
| Dr. Chulani Karunatilake Ph.D. | Chief Technology Officer |
| Ellen A. Lubman M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 8, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |